A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer
机构：[1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing,China[2]Cancer Center, Jinling Hospital, Nanjing, China[3]Department of NuclearMedicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China[4]Department of Nuclear Medicine, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[5]Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University,Guilin, China[6]Department of Nuclear Medicine, Nanjing First Hospital, Nanjing,China[7]Department of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, China[8]Department of Nuclear Medicine, Union Hospital affiliated to Tongji Medical Collegeof Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[9]Department ofNuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou,China[10]Department of Nuclear Medicine, The First Affiliated Hospital of AnhuiMedical University, Hefei, China[11]Department of Nuclear Medicine, The First AffiliatedHospital of Nanchang University, Nanchang, China[12]Department of NuclearMedicine, The fourth Hospital of Hebei Medical University & Hebei Tumor Hospital,Shijiazhuang, China河北医科大学第四医院[13]Department of Endocrinology, JiangYuan Hospital Affiliated toJiangsu Institute of Nuclear Medicine,Wuxi, China[14]Department of Nuclear Medicine,Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[15]Department of Nuclear Medicine,Shanxi Provincial Cancer Hospital, Taiyuan, China[16]Department of Nuclear Medicine,The First Hospital of Jilin University, Changchun, China[17]Otorhinolaryngology - Headand Neck Surgery, The Fourth Hospital of Hebei Medical University (Hebei CancerHospital), Shijiazhuang, China河北医科大学第四医院[18]Department of Nuclear Medicine, The China-JapanUnion Hospital of Jilin University, Changchun, China[19]Medical Oncology, PekingUniversity Internation Hospital, Beijing, China[20]Department of Thyroid Surgery, TheFirst Hospital of Jilin University, Changchun, China
第一作者机构：[1]Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing,China
推荐引用方式(GB/T 7714)：
Lin Y-S.,Qin S-K.,Li Z-Y.,et al.A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer[J].ANNALS OF ONCOLOGY.2020,31:S1215-S1215.doi:10.1016/j.annonc.2020.08.2333.
APA：
Lin, Y-S.,Qin, S-K.,Li, Z-Y.,Yang, H.,Fu, W....&Chen, G..(2020).A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer.ANNALS OF ONCOLOGY,31,
MLA：
Lin, Y-S.,et al."A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer".ANNALS OF ONCOLOGY 31.(2020):S1215-S1215
医学